Schrodinger received approximately $57 million in cash from the completion of Eli Lilly’s acquisition of Ajax, and may receive additional milestone payments.
Key Highlights:
- Schrodinger got a cash payment of about $57 million tied to Eli Lilly’s acquisition of Ajax.
- Schrodinger is eligible for further cash payments contingent on Ajax achieving specified clinical and regulatory milestones.
- Disclosure furnished under Regulation FD and not filed for purposes of Exchange Act Section 18 or incorporation by reference.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.